These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 31289117

  • 21. Immunoaffinity-free chromatographic purification of ovarian cancer biomarker CA125 (MUC16) from blood serum enables mass spectrometry characterization.
    Schuster-Little N, Sokolovsky AD, Gentry A, Saraf A, Etzel MR, Patankar MS, Whelan RJ.
    Anal Methods; 2024 Sep 26; 16(37):6337-6348. PubMed ID: 39177265
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125.
    Jin C, Yang M, Han X, Chu H, Zhang Y, Lu M, Wang Z, Xu X, Liu W, Wang F, Ju S.
    J Ovarian Res; 2019 Nov 25; 12(1):114. PubMed ID: 31767040
    [Abstract] [Full Text] [Related]

  • 23. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
    Elschenbroich S, Ignatchenko V, Clarke B, Kalloger SE, Boutros PC, Gramolini AO, Shaw P, Jurisica I, Kislinger T.
    J Proteome Res; 2011 May 06; 10(5):2286-99. PubMed ID: 21491939
    [Abstract] [Full Text] [Related]

  • 24. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
    Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.
    Clin Biochem; 2013 Oct 06; 46(15):1462-8. PubMed ID: 23528302
    [Abstract] [Full Text] [Related]

  • 25. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
    Timms JF, Arslan-Low E, Kabir M, Worthington J, Camuzeaux S, Sinclair J, Szaub J, Afrough B, Podust VN, Fourkala EO, Cubizolles M, Kronenberg F, Fung ET, Gentry-Maharaj A, Menon U, Jacobs I.
    Proteomics Clin Appl; 2014 Dec 06; 8(11-12):982-93. PubMed ID: 25290619
    [Abstract] [Full Text] [Related]

  • 26. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA, Abdou AM.
    Curr Probl Cancer; 2019 Oct 06; 43(5):450-460. PubMed ID: 30670303
    [Abstract] [Full Text] [Related]

  • 27. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
    Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM.
    PLoS One; 2015 Oct 06; 10(3):e0121112. PubMed ID: 25799488
    [Abstract] [Full Text] [Related]

  • 28. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
    Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW.
    Cancer Res; 2004 Aug 15; 64(16):5882-90. PubMed ID: 15313933
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A.
    Clin Chem Lab Med; 2013 Sep 15; 51(9):1815-24. PubMed ID: 24013103
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heinzelmann-Schwarz V.
    Gynecol Oncol; 2011 Jun 01; 121(3):487-91. PubMed ID: 21420727
    [Abstract] [Full Text] [Related]

  • 35. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC, AOCS Study Group.
    Clin Cancer Res; 2017 Oct 01; 23(19):5912-5922. PubMed ID: 28637689
    [Abstract] [Full Text] [Related]

  • 36. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics.
    Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, Zivny J, Petrak J.
    Oncol Rep; 2012 Feb 01; 27(2):318-24. PubMed ID: 22020625
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov 01; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.
    Tumour Biol; 2015 Feb 01; 36(2):1045-53. PubMed ID: 25326813
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.